Shannon Connelly

During a recent <em>Targeted Oncology </em>case-based peer perspectives live dinner event, Massimo Cristofanilli, MD, explained the options for treatment based on the case scenario of a woman with ER-positive breast cancer.<br /> &nbsp;

During a recent&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation, Tanios Bekaii-Saab, MD, discussed with a group of physicians the treatment options for patients with gastrointestinal cancers and the characteristics that influence his decision making. Bekaii-Saab explained his clinical decisions based on the case scenario of one patient with colorectal cancer and one with hepatocellular carcinoma.

Patients with aggressive papillary thyroid cancer may be good candidates for treatment with anti&ndash;PD-(L)1 immunotherapy due to elevated levels of serum PD-L1, according to findings from a new study presented during the 2019 AACR-AHNS Head and Neck Cancer Conference.

Olga K. Weinberg, MD, discusses how genomic testing has evolved over the years and how she envisions the role of NGS will change as more is learned about genetic mutations.&nbsp;

The FDA has lifted the partial clinical hold placed on the phase III AIM2CERV trial, which is evaluating axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer, according to Advaxis, the developer of the investigational immunotherapy agent.

Treatment with vaginal cuff brachytherapy plus paclitaxel and carboplatin chemotherapy was not found to be superior to pelvic radiation therapy in patients with high-intermediate and high-risk early-stage endometrial cancer, according to findings from a phase III trial recently published in the <em>Journal of Clinical Oncology</em>.

Patient-reported outcomes from the phase III myeloma X trial suggested that although patients with relapsed multiple myeloma who received salvage autologous stem cell transplantation had an initial reduction in quality of life and experienced a greater impact of adverse events, they had better long-term outcomes compared with patients who received nontransplantation consolidation.

The first patient has been dosed in a phase III clinical trial investigating the addition of uproleselan (GMI-1271) to standard 7+3 chemotherapy in older patients with previously untreated acute myeloid leukemia.

During a&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, explained to a group of physicians the treatment considerations and decisions he makes when seeing a patient with mantle cell lymphoma in the clinic.

The FDA has granted tebentafusp (IMCgp100) a fast track designation for the treatment of patients with HLA-A*0201-positive previously untreated metastatic uveal melanoma, according to Immunocore Limited, the company developing the novel immunotherapy agent.

Although biomarker discovery has been a challenge in colorectal cancer, new findings suggest the presence of select polymorphisms may be promising in predicting treatment outcomes in patients with colorectal cancer.

Recently published data from a retrospective study suggest that patients with thyroid cancer who have T-cell lymphopenia are more likely to have aggressive tumors. Investigators believe this information can be used to identify potential therapeutic targets in these patients.

A pivotal phase III INNOVATE-3 trial investigating the efficacy of tumor-treating fields (TTFields; Optune) combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer has been initiated, according to Novocure, the company developing the device.

The first patient has been dosed in a phase II study investigating the safety and tolerability of the novel agent LiPlaCis for the treatment of advanced or refractory prostate cancer.

Based on 2 case scenarios, H. Jack West, MD, discusses treatment options and the data that support these options for the management of squamous and nonsquamous non&ndash;small cell lung cancer.

The FDA has granted an orphan drug designation to the investigational agent etoposide toniribate for the treatment of patients with relapsed/refractory biliary tract cancer, according to Imbrium Therapeutics, the company developing the topoisomerase II inhibitor.

The treatment regimen of rituximab, bendamustine, bortezomib, and dexamethasone demonstrated activity and a manageable safety profile as a first-line therapy for patients with mantle cell lymphoma aged 65 years or older, according to findings from a prospective, multicenter phase II study.

Brian T. Hill, MD, PhD,&nbsp;discusses real-world findings with axi-cel in patients with DLBCL and how these findings can be used to inform practice.

Gabriela S. Hobbs, MD,&nbsp;discusses recent advances in the treatment of myelofibrosis and other MPNs, as well as clinical trials she is currently working on in this space.

Krish Patel, MD,&nbsp;discusses some of the most significant mantle cell lymphoma data presented during the 2018 ASH Annual Meeting and how the use of BTK inhibitors will evolve going forward.

Maria-Victoria Mateos, MD, PhD, discusses updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.&nbsp;

David S. Hong, MD,&nbsp;discusses the use of larotrectinib in patients with thyroid cancer, as well as what is on the horizon with this agent and other TRK inhibitors.

The first patient has been enrolled in the pivotal phase III AGENT trial, which is investigating arfolitixorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab compared with FOLFOX plus bevacizumab in patients with metastatic colorectal cancer, according to Isofol Medical AB, the company developing arfolitixorin.

Patients with thyroid cancer classified as having low risk of disease recurrence can be treated safely with a lower dose of radiation following surgery, compared with the standard higher dose, according to long-term findings from the HiLo trial presented at the National Cancer Research Institute (NCRI) Cancer Conference.

More research is still needed to determine the risk of developing a subsequent malignant neoplasm following radioactive iodine treatment for thyroid cancer, according to findings that were presented during the Annual Meeting of the American Thyroid Association and published in <em>Thyroid</em>.

Hussein A. Tawbi, MD,&nbsp;discusses the expansion of the treatment armamentarium for adjuvant melanoma and the next steps with research in this patient population.<br /> &nbsp;

The first patient has been dosed in the phase III FIGHT trial investigating bemarituzumab (FPA144) combined with chemotherapy in patients with previously untreated advanced gastric or gastroesophageal junction cancer, according to Five Prime Therapeutics, the developer of the isoform-selective FGF receptor 2b antibody.

While significant progress has been made in the fight against cancer, including a decline in cancer deaths, the number of people projected to be diagnosed with cancer is on the rise, and there is still more work to be done, according to the newly released American Association for Cancer Research Cancer Progress Report.

Sanjiv S. Agarwala, MD, discusses the promising activity seen with the combination of pembrolizumab and entinostat in patients with advanced melanoma, according to initial results from the ongoing ENCORE 601 trial.

The combination of apatinib and oral etoposide showed promising efficacy and a manageable safety profile in patients with platinum-resistant or platinum-refractory ovarian cancer, according to findings from the phase II AEROC trial recently published in <em>The Lancet Oncology</em>.